Phase I pharmacodynamic (PD) and pharmacokinetic (PIK) analysis of the sorafenib (S) and erlotinib (E) combination in patients with advanced solid tumors

被引：0
|
作者：
Le Tourneau, C. [1 ]
Duran, I. [1 ]
Chen, E. [1 ]
Wang, L. [2 ]
Tsao, M. [3 ]
Hedley, D. [3 ]
Phan, N. [3 ]
Do, T. [3 ]
Metser, U. [4 ]
Siu, L. [1 ]
机构：
[1] Princess Margaret Hosp, Dept Med Oncol, Drug Dev Program, Toronto, ON M4X 1K9, Canada
[2] Princess Margaret Hosp, Dept Biostat, Toronto, ON M4X 1K9, Canada
[3] Princess Margaret Hosp, Correlat Studies Dept, Toronto, ON M4X 1K9, Canada
[4] Princess Margaret Hosp, Dept Radiol, Toronto, ON M4X 1K9, Canada
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72344-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [31] A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies
    Chia, S. K.
    Chi, K. N.
    Kollmannsberger, C.
    Paton, K.
    Bhagat, K.
    D'Aloisio, S.
    Das-Gupta, A.
    Kletzl, H.
    Zwanziger, E.
    Gelmon, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors
    Mackay, HJ
    Hoekstra, R
    Eskens, FALM
    Loos, WJ
    Crawford, D
    Voi, M
    Van Vreckem, A
    Evans, TRJ
    Verweij, J
    CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2636 - 2644
  • [33] A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies
    Chia, S.
    Chi, K.
    Kollmannsberger, C.
    Paton, K.
    Bhagat, K.
    D'Aloisi, S.
    Das-Gupta, A.
    Kletzl, H.
    Zwanziger, E.
    Gelmon, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 109 - 109
  • [34] Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
    Maja J. A. de Jonge
    Paul Hamberg
    Jaap Verweij
    Shawna Savage
    A. Benjamin Suttle
    Jeffrey Hodge
    Thangam Arumugham
    Lini N. Pandite
    Herbert I. Hurwitz
    Investigational New Drugs, 2013, 31 : 751 - 759
  • [35] Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
    de Jonge, Maja J. A.
    Hamberg, Paul
    Verweij, Jaap
    Savage, Shawna
    Suttle, A. Benjamin
    Hodge, Jeffrey
    Arumugham, Thangam
    Pandite, Lini N.
    Hurwitz, Herbert I.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 751 - 759
  • [36] Phase I study of paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Kummer, G.
    Strumberg, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Phase I study with paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Heuer, V
    Kummer, G.
    Strumberg, D.
    ONKOLOGIE, 2011, 34 : 110 - 110
  • [38] Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
    Eskens, Ferry A. L. M.
    Ramos, Francisco J.
    Burger, Herman
    O'Brien, James P.
    Piera, Adelaida
    de Jonge, Maja J. A.
    Mizui, Yoshiharu
    Wiemer, Erik A. C.
    Carreras, Maria Josepa
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6296 - 6304
  • [39] Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    Minami, Hironobu
    Kawada, Kenji
    Ebi, Hiromichi
    Kitagawa, Koichi
    Kim, Yon-il
    Araki, Kazuhiro
    Mukai, Hirofumi
    Tahara, Makoto
    Nakajima, Hikaru
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (07): : 1492 - 1498
  • [40] Combined autophagy and HDAC inhibition A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors
    Mahalingam, Devalingam
    Mita, Monica
    Sarantopoulos, John
    Wood, Leslie
    Amaravadi, Ravi K.
    Davis, Lisa E.
    Mita, Alain
    Curiel, Tyler J.
    Espitia, Claudia M.
    Nawrocki, Steffan T.
    Giles, Francis J.
    Carew, Jennifer S.
    AUTOPHAGY, 2014, 10 (08) : 1403 - 1414
12345